We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Epix Pharmaceuticals has announced the initiation of a Phase I multiple-ascending-dose clinical trial to study the safety, tolerability, pharmacokinetics and pharmacodynamics of PRX-07034 administered once-daily for 28 days in a population of otherwise healthy obese adults with body mass indices between 30 and 42 kg/m2.
Carrington Laboratories has presented data on a nasal powder influenza vaccine that incorporates inactivated whole virion antigen in the GelVac dry powder delivery system, a unique in situ gelling powder formulation.
ViroPharma announced that patient dosing has begun in a Phase II study of HCV-796, a unique orally dosed hepatitis C viral polymerase inhibitor that interferes with the replication of hepatitis C virus (HCV).
Renovo has announced positive Phase II clinical trial results for its lead drug, Juvista, in a 12-month proof-of-concept study of scar reduction at split-thickness skin graft donor sites.
PTC Therapeutics has announced encouraging data from a Phase II clinical trial of PTC124 in patients with Duchenne muscular dystrophy (DMD) due to a nonsense mutation.
Somaxon Pharmaceuticals has announced positive results from the company's Phase III clinical trial evaluating Silenor (doxepin HCl) in adults with transient insomnia.
Allos Therapeutics announced that an independent data monitoring committee (DMC) has completed a second planned interim analysis of data from the company's pivotal Phase III ENRICH trial of Efaproxyn (efaproxiral) plus whole-brain radiation therapy in women with brain metastases originating from breast cancer, and has recommended that the trial continue to the final efficacy analysis.
Patients with ulcerative colitis (UC) treated with Remicade (infliximab) had an approximate 50 percent reduction in mean number of hospitalizations per year compared with placebo, according to an analysis of long-term data from a Phase III clinical trial, the ACT 1 trial, presented by Centocor at the American College of Gastroenterology meeting.